gvtcx

Support of existing NHSBT Low Density Lipid (LDL) Removal Apheresis System

NHS Blood and Transplant, Bristol Published 22 Apr 2025 Find a Tender

key details

Value£100,000 (£120,000 inc. VAT)
Statusplanning
Category (CPV) 33000000 +3 more
SME suitableYes
OCIDocds-h6vhtk-0505dc

description

NHSBT would like to consult the market to establish the likely level of interest for the consumables and maintenance where Low Density Lipoprotein removal is performed on Fresenius Medical Care (UK) Ltd. ART Universal machines at the following sites: Bristol and Leeds. NHS Blood and Transplant (NHBST) is a Special Health Authority within the NHS and is responsible for the provision of blood components and a range of associated laboratory and patient therapeutic services to hospitals in England and Wales. Therapeutic Apheresis Services (TAS) provide lifesaving and life-enhancing therapies to adults and children from across a range of clinical specialties. Patients receive treatment either at their hospital bedside or where clinically appropriate as an outpatient in an NHS Blood and Transplant (NHSBT) unit. NHSBT provides regional access to apheresis services from 11 dedicated units across England and Wales.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
22 Apr 2025 Preliminary market engagement (UK2) Procurement Act 2023 016325-2025

more from NHS Blood and Transplant, Bristol

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.